Detailed Analysis of Current Migraine Treatment Trends by Treatment Groups in a Large Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases
Olya Besedina1, Mariya Petrova1, Brendan Hare3, Alankar Gupta2, Shaheen Lakhan2
1Medical Affairs, 2Medical Office, Click Therapeutics Inc., 3Boehringer-Ingelheim Pharmaceuticals
Objective:
We evaluated a large subset of the US Migraine population under various groups stratified by medication to analyze current migraine treatment trends.
Background:
With the emergence of calcitonin gene-related peptide (anti-CGRP) medications the migraine treatment landscape has evolved recently and a detailed review of a large subset of the US Migraine population may offer insight into current prescription trends.
Design/Methods:
Based on ICD-10 codes (Health Verity claims data; 8/2018-7/2021; N=187,780) Chronic vs. Other migraine groups were defined under the following: anti-CGRP, non-specific migraine preventive treatment, migraine-specific acute treatment, non-specific acute treatment, and no treatment. Baseline and Follow-up periods defined as 12 months prior and after the index.
Results:
At baseline, Chronic Migraine group (N=21,879) were further subdivided into: non-specific migraine preventive treatment (41.2%), no treatment (17.6%), anti-CGRP (16.1%), migraine-specific acute (15.0%), and non-specific acute treatment (10.0%) groups. Other Migraine group (N=165,901) were divided under following subgroups: non-specific migraine preventive treatment group (34.4%), no treatment (26.9%), migraine-specific acute (18.9%), non-specific acute treatment (15.4%), and anti-CGRP (4.4%) groups.
The anti-CGRP treatment group had the highest percentage of all-cause Neurology visits among the 5 treatment groups in Chronic and Other Migraine types during Baseline and Follow-up periods. Acute Non-Specific treatment groups had the most frequent visits to the emergency department in both migraine types during Baseline and Follow-up.
Conclusions:
Prescription trends from a large subset of the US Migraine population revealed significant differences among treatment groups. The recent introduction of novel calcitonin gene-related peptide (anti-CGRP) medications has transformed the migraine treatment landscape.